Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor

Lewis MacKenzie, Pamela McCall, Sophia Hatziieremia, Jamie Catlow, Claire Adams, Peter McArdle, Morag Seywright, Claire Tanahill, Andrew Paul, Mark Underwood, Simon Mackay, Robin Plevin, Joanne Edwards

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Despite recent advances in prostate cancer treatments, disease recurrence is common and associated with significant morbidity and mortality. The need for more effective antitumor agents has led researchers to target signaling pathways that drive tumorigenesis by modulating or bypassing androgen receptor signaling--attenuation or blockade of which current treatments aim to effect. The transcription factor nuclear factor κB/p65 has been implicated in prostate cancer progression; however, few studies have examined the involvement of nuclear factor κB in hormone-naive disease. We used immunohistochemistry to investigate expression of p65, androgen receptor, Ki-67, and phosphorylation status of p65 at serine 536, in 154 tumor samples taken from patients before hormone ablation or radical treatment. Nuclear p65 expression was significantly associated with disease-specific mortality: P = .005; hazard ratio, 2.2. When patients were stratified according to androgen receptor status, this relationship was abolished in low androgen receptor-expressing patients and potentiated in high androgen receptor-expressing patients: P = .002; hazard ratio, 3.1. Ki-67 expression was also prognostic of shorter disease-specific mortality: P = .001; hazard ratio, 2.3. When the cohort was stratified according to androgen receptor status, this relationship held for high androgen receptor expressers but not low expressers: P = .0003; hazard ratio, 3.5. Neither androgen receptor nor p65 phosphorylated at S536 were significantly prognostic when considered individually. These data suggest that future prostate cancer treatments that target nuclear factor κB signaling should be assigned primarily to patients with concomitant high nuclear p65 and androgen receptor expression.
LanguageEnglish
Pages1491-500
Number of pages10
JournalHuman pathology
Volume43
Issue number9
Early online date9 Mar 2012
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Androgen Receptors
Cytoplasmic and Nuclear Receptors
Prostatic Neoplasms
Hormones
Mortality
Therapeutics
Antineoplastic Agents
Serine
Carcinogenesis
Transcription Factors
Immunohistochemistry
Phosphorylation
Research Personnel
Morbidity
Recurrence

Keywords

  • prostate cancer
  • hormone-naive prostate cancer
  • castrate-resistant prostate cancer
  • androgen receptor
  • nuclear factor kappa B

Cite this

MacKenzie, L., McCall, P., Hatziieremia, S., Catlow, J., Adams, C., McArdle, P., ... Edwards, J. (2012). Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Human pathology, 43(9), 1491-500. https://doi.org/10.1016/j.humpath.2011.11.009
MacKenzie, Lewis ; McCall, Pamela ; Hatziieremia, Sophia ; Catlow, Jamie ; Adams, Claire ; McArdle, Peter ; Seywright, Morag ; Tanahill, Claire ; Paul, Andrew ; Underwood, Mark ; Mackay, Simon ; Plevin, Robin ; Edwards, Joanne. / Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. In: Human pathology. 2012 ; Vol. 43, No. 9. pp. 1491-500.
@article{225ed93f900145209d839cf85b113e52,
title = "Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor",
abstract = "Despite recent advances in prostate cancer treatments, disease recurrence is common and associated with significant morbidity and mortality. The need for more effective antitumor agents has led researchers to target signaling pathways that drive tumorigenesis by modulating or bypassing androgen receptor signaling--attenuation or blockade of which current treatments aim to effect. The transcription factor nuclear factor κB/p65 has been implicated in prostate cancer progression; however, few studies have examined the involvement of nuclear factor κB in hormone-naive disease. We used immunohistochemistry to investigate expression of p65, androgen receptor, Ki-67, and phosphorylation status of p65 at serine 536, in 154 tumor samples taken from patients before hormone ablation or radical treatment. Nuclear p65 expression was significantly associated with disease-specific mortality: P = .005; hazard ratio, 2.2. When patients were stratified according to androgen receptor status, this relationship was abolished in low androgen receptor-expressing patients and potentiated in high androgen receptor-expressing patients: P = .002; hazard ratio, 3.1. Ki-67 expression was also prognostic of shorter disease-specific mortality: P = .001; hazard ratio, 2.3. When the cohort was stratified according to androgen receptor status, this relationship held for high androgen receptor expressers but not low expressers: P = .0003; hazard ratio, 3.5. Neither androgen receptor nor p65 phosphorylated at S536 were significantly prognostic when considered individually. These data suggest that future prostate cancer treatments that target nuclear factor κB signaling should be assigned primarily to patients with concomitant high nuclear p65 and androgen receptor expression.",
keywords = "prostate cancer, hormone-naive prostate cancer, castrate-resistant prostate cancer, androgen receptor, nuclear factor kappa B",
author = "Lewis MacKenzie and Pamela McCall and Sophia Hatziieremia and Jamie Catlow and Claire Adams and Peter McArdle and Morag Seywright and Claire Tanahill and Andrew Paul and Mark Underwood and Simon Mackay and Robin Plevin and Joanne Edwards",
note = "Copyright {\circledC} 2012 Elsevier Inc. All rights reserved.",
year = "2012",
month = "9",
doi = "10.1016/j.humpath.2011.11.009",
language = "English",
volume = "43",
pages = "1491--500",
journal = "Human pathology",
issn = "1532-8392",
publisher = "W.B. Saunders Ltd",
number = "9",

}

MacKenzie, L, McCall, P, Hatziieremia, S, Catlow, J, Adams, C, McArdle, P, Seywright, M, Tanahill, C, Paul, A, Underwood, M, Mackay, S, Plevin, R & Edwards, J 2012, 'Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor' Human pathology, vol. 43, no. 9, pp. 1491-500. https://doi.org/10.1016/j.humpath.2011.11.009

Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. / MacKenzie, Lewis; McCall, Pamela; Hatziieremia, Sophia; Catlow, Jamie; Adams, Claire; McArdle, Peter; Seywright, Morag; Tanahill, Claire; Paul, Andrew; Underwood, Mark; Mackay, Simon; Plevin, Robin; Edwards, Joanne.

In: Human pathology, Vol. 43, No. 9, 09.2012, p. 1491-500.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nuclear factor κB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor

AU - MacKenzie, Lewis

AU - McCall, Pamela

AU - Hatziieremia, Sophia

AU - Catlow, Jamie

AU - Adams, Claire

AU - McArdle, Peter

AU - Seywright, Morag

AU - Tanahill, Claire

AU - Paul, Andrew

AU - Underwood, Mark

AU - Mackay, Simon

AU - Plevin, Robin

AU - Edwards, Joanne

N1 - Copyright © 2012 Elsevier Inc. All rights reserved.

PY - 2012/9

Y1 - 2012/9

N2 - Despite recent advances in prostate cancer treatments, disease recurrence is common and associated with significant morbidity and mortality. The need for more effective antitumor agents has led researchers to target signaling pathways that drive tumorigenesis by modulating or bypassing androgen receptor signaling--attenuation or blockade of which current treatments aim to effect. The transcription factor nuclear factor κB/p65 has been implicated in prostate cancer progression; however, few studies have examined the involvement of nuclear factor κB in hormone-naive disease. We used immunohistochemistry to investigate expression of p65, androgen receptor, Ki-67, and phosphorylation status of p65 at serine 536, in 154 tumor samples taken from patients before hormone ablation or radical treatment. Nuclear p65 expression was significantly associated with disease-specific mortality: P = .005; hazard ratio, 2.2. When patients were stratified according to androgen receptor status, this relationship was abolished in low androgen receptor-expressing patients and potentiated in high androgen receptor-expressing patients: P = .002; hazard ratio, 3.1. Ki-67 expression was also prognostic of shorter disease-specific mortality: P = .001; hazard ratio, 2.3. When the cohort was stratified according to androgen receptor status, this relationship held for high androgen receptor expressers but not low expressers: P = .0003; hazard ratio, 3.5. Neither androgen receptor nor p65 phosphorylated at S536 were significantly prognostic when considered individually. These data suggest that future prostate cancer treatments that target nuclear factor κB signaling should be assigned primarily to patients with concomitant high nuclear p65 and androgen receptor expression.

AB - Despite recent advances in prostate cancer treatments, disease recurrence is common and associated with significant morbidity and mortality. The need for more effective antitumor agents has led researchers to target signaling pathways that drive tumorigenesis by modulating or bypassing androgen receptor signaling--attenuation or blockade of which current treatments aim to effect. The transcription factor nuclear factor κB/p65 has been implicated in prostate cancer progression; however, few studies have examined the involvement of nuclear factor κB in hormone-naive disease. We used immunohistochemistry to investigate expression of p65, androgen receptor, Ki-67, and phosphorylation status of p65 at serine 536, in 154 tumor samples taken from patients before hormone ablation or radical treatment. Nuclear p65 expression was significantly associated with disease-specific mortality: P = .005; hazard ratio, 2.2. When patients were stratified according to androgen receptor status, this relationship was abolished in low androgen receptor-expressing patients and potentiated in high androgen receptor-expressing patients: P = .002; hazard ratio, 3.1. Ki-67 expression was also prognostic of shorter disease-specific mortality: P = .001; hazard ratio, 2.3. When the cohort was stratified according to androgen receptor status, this relationship held for high androgen receptor expressers but not low expressers: P = .0003; hazard ratio, 3.5. Neither androgen receptor nor p65 phosphorylated at S536 were significantly prognostic when considered individually. These data suggest that future prostate cancer treatments that target nuclear factor κB signaling should be assigned primarily to patients with concomitant high nuclear p65 and androgen receptor expression.

KW - prostate cancer

KW - hormone-naive prostate cancer

KW - castrate-resistant prostate cancer

KW - androgen receptor

KW - nuclear factor kappa B

UR - http://www.journals.elsevier.com/human-pathology

U2 - 10.1016/j.humpath.2011.11.009

DO - 10.1016/j.humpath.2011.11.009

M3 - Article

VL - 43

SP - 1491

EP - 1500

JO - Human pathology

T2 - Human pathology

JF - Human pathology

SN - 1532-8392

IS - 9

ER -